Abstract
Subsequently to the publication of the above paper, the authors have realized that the images presented in Fig.1A were selected erroneously (essentially, the images for group 'AdBMP9+++' were chosen to represent the group 'AdGFP'). A corrected version of Fig.1, including the correct data for the experiments depicted in Fig.1A, is shown opposite. Note that this change does not affect the results or the conclusions reported in this paper, and all the authors agree to this correction. The authors apologize to the Editor and to the readership of the Journal for any inconvenience caused. [the original article was published in International Journal of Oncology 50: 1363‑1371, 2017; DOI: 10.3892/ijo.2017.3910].
Highlights
All-trans retinoic acid restored the osteogenic ability of BMP9 in osteosarcoma through the p38 MAPK pathway
To the publication of the above paper, the authors have realized that the images presented in Fig. 1A were selected erroneously
A corrected version of Fig. 1, including the correct data for the experiments depicted in Fig. 1A, is shown opposite
Summary
All-trans retinoic acid restored the osteogenic ability of BMP9 in osteosarcoma through the p38 MAPK pathway
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
